{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:17:06Z","timestamp":1791919026128,"version":"4.3.4"},"reference-count":51,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Pyroptosis is a type of cell death that is caspase-1 (Casp-1) dependent, which leads to a rapid cell lysis, and it is linked to the inflammasome. We recently showed that pyroptotic cell death occurs in Huntington\u2019s disease (HD). Moreover, we previously described the beneficial effects of a PARP-1 inhibitor in HD. In this study, we investigated the neuroprotective effect of Olaparib, an inhibitor of PARP-1, in the mouse model of Huntington\u2019s disease. R6\/2 mice were administered Olaparib or vehicle from pre-symptomatic to late stages. Behavioral studies were performed to investigate clinical effects of the compound. Immunohistochemical and Western blotting studies were performed to evaluate neuroprotection and the impact of the compound on the pathway of neuronal death in the HD mice. Our results indicate that Olaparib administration starting from the pre-symptomatic stage of the neurodegenerative disease increased survival, ameliorated the neurological deficits, and improved clinical outcomes in neurobehavioral tests mainly by modulating the inflammasome activation. These results suggest that Olaparib, a commercially available drug already in use as an anti-neoplastic compound, exerts a neuroprotective effect and could be a useful pharmaceutical agent for Huntington\u2019s disease therapy.<\/jats:p>","DOI":"10.3390\/cells9102286","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T21:42:21Z","timestamp":1602798141000},"page":"2286","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Modulation of Inflammasome and Pyroptosis by Olaparib, a PARP-1 Inhibitor, in the R6\/2 Mouse Model of Huntington\u2019s Disease"],"prefix":"10.3390","volume":"9","author":[{"given":"Emanuela","family":"Paldino","sequence":"first","affiliation":[{"name":"Laboratory of Neuroanatomy, IRCCS Fondazione Santa Lucia, 00143 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"D\u2019Angelo","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina dei Sistemi, Universit\u00e0 di Roma 2 Tor Vergata, 00133 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daunia","family":"Laurenti","sequence":"additional","affiliation":[{"name":"Laboratory of Neuroanatomy, IRCCS Fondazione Santa Lucia, 00143 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Angeloni","sequence":"additional","affiliation":[{"name":"Laboratory of Neuroanatomy, IRCCS Fondazione Santa Lucia, 00143 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Sancesario","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina dei Sistemi, Universit\u00e0 di Roma 2 Tor Vergata, 00133 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca R.","family":"Fusco","sequence":"additional","affiliation":[{"name":"Laboratory of Neuroanatomy, IRCCS Fondazione Santa Lucia, 00143 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/01688638708405354","article-title":"Memory failure in Huntington\u2019s disease","volume":"9","author":"Wilson","year":"1987","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"The Huntington\u2019s Disease Collaborative Research Group (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell, 72, 893\u2013971.","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0166-2236(95)93943-R","article-title":"Genetics and molecular biology of Huntington\u2019s disease","volume":"18","author":"Albin","year":"1995","journal-title":"Trends Neurosci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1006\/exnr.1997.6724","article-title":"Relative resistance of striatal neurons containing calbindin or parvalbumin to quinolinic acid-mediated excitotoxicity compared to other striatal neuron types","volume":"149","author":"Harris","year":"1998","journal-title":"Exp. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/cne.10295","article-title":"Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6\/2 transgenic mice","volume":"449","author":"Meade","year":"2002","journal-title":"J. Comp. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0168-9525(03)00074-X","article-title":"Transcriptional abnormalities in Huntington disease","volume":"19","author":"Sugars","year":"2003","journal-title":"Trends Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1471-4159.2003.02002.x","article-title":"Pro-apoptotic protein kinase C\u03b4 is associated with intranuclear inclusions in a transgenic model of Huntington\u2019s disease","volume":"87","author":"Zemskov","year":"2003","journal-title":"J. Neurochem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/exnr.1998.7006","article-title":"Recent advances on the pathogenesis of Huntington\u2019s disease","volume":"157","author":"Petersen","year":"1999","journal-title":"Exp. Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00401-004-0957-5","article-title":"Expression pattern of apoptosis-related markers in Huntington\u2019s disease","volume":"109","author":"Vis","year":"2005","journal-title":"Acta Neuropathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/00001756-199505090-00026","article-title":"In situ evidence for DNA fragmentation in Huntington\u2019s disease striatum and Alzheimer\u2019s disease temporal lobes","volume":"6","author":"Dragunow","year":"1995","journal-title":"Neuroreport"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1523\/JNEUROSCI.15-05-03775.1995","article-title":"Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models","volume":"15","author":"Hedreen","year":"1995","journal-title":"J. Neurosci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1006\/exnr.1995.1029","article-title":"DNA end labeling (TUNEL) in Huntington\u2019s disease and other neuropathological conditions","volume":"133","author":"Thomas","year":"1995","journal-title":"Exp. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/ng0896-442","article-title":"Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract","volume":"13","author":"Goldberg","year":"1996","journal-title":"Nat. Genet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0278-5846(03)00021-6","article-title":"Apoptosis in Huntington\u2019s disease","volume":"27","author":"Hickey","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1600-065X.2011.01044.x","article-title":"Caspase-1-induced pyroptotic cell death","volume":"243","author":"Miao","year":"2011","journal-title":"Immunol. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41419-020-2248-z","article-title":"Inhibition of AIM2 inflammasome activation alleviates GSDMD-induced pyroptosis in early brain injury after subarachnoid haemorrhage","volume":"11","author":"Yuan","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/nri2725","article-title":"NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production?","volume":"10","author":"Tschopp","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","article-title":"Pattern recognition receptors and inflammation","volume":"140","author":"Takeuchi","year":"2010","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","article-title":"The inflammasomes","volume":"140","author":"Schroder","year":"2010","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s12035-017-0467-9","article-title":"NLRP3 Inflammasome Inhibitor Ameliorates Amyloid Pathology in a Mouse Model of Alzheimer\u2019s Disease","volume":"55","author":"Yin","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41420-020-00293-z","article-title":"Pyroptotic cell death in the R6\/2 mouse model of Huntington\u2019s disease: New insight on the inflammasome","volume":"6","author":"Paldino","year":"2020","journal-title":"Cell Death Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/ijc.20342","article-title":"Poly(ADP-ribosyl)ation inhibitors: Promising drug candidates for a wide variety of pathophysiologic conditions","volume":"111","author":"Beneke","year":"2004","journal-title":"Int. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"18308","DOI":"10.1073\/pnas.0606526103","article-title":"Poly(ADP-ribose) (PAR) polymer is a death signal","volume":"103","author":"Andrabi","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0006-8993(03)03362-6","article-title":"Deleterious poly(ADP-ribose)polymerase-1 pathway activation in traumatic brain injury in rat","volume":"989","author":"Besson","year":"2003","journal-title":"Brain Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.tox.2005.06.023","article-title":"Effect of 3-aminobenzamide, PARP inhibitor, on matrix metalloproteinase-9 level in plasma and brain of ischemic stroke model","volume":"214","author":"Koh","year":"2005","journal-title":"Toxicology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.neuint.2006.06.006","article-title":"Poly(ADP-ribose) polymerase-1 inhibition protects the brain against systemic inflammation","volume":"49","author":"Czapski","year":"2006","journal-title":"Neurochem. Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/nm1097-1089","article-title":"Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia","volume":"3","author":"Eliasson","year":"1997","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/00004647-199711000-00002","article-title":"Ischemic brain injury is mediated by the activation of poly(ADP-ribose) polymerase","volume":"17","author":"Endres","year":"1997","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1126\/science.1072221","article-title":"Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor","volume":"297","author":"Yu","year":"2002","journal-title":"Science"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"18314","DOI":"10.1073\/pnas.0606528103","article-title":"Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death","volume":"103","author":"Yu","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.expneurol.2009.03.020","article-title":"Poly(ADP-ribose) signals to mitochondrial AIF: A key event in parthanatos","volume":"218","author":"Wang","year":"2009","journal-title":"Exp. Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"35767","DOI":"10.1074\/jbc.M507075200","article-title":"Pivotal role of Akt activation in mitochondrial protection and cell survival by poly(ADP-ribose)polymerase-1 inhibition in oxidative stress","volume":"280","author":"Tapodi","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Cardinale, A., Paldino, E., Giamp\u00e0, C., Bernardi, G., and Fusco, F.R. (2015). PARP-1 Inhibition is neuroprotective in the R6\/2 mouse model of Huntington\u2019s disease. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0134482"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1602\/neurorx.1.3.298","article-title":"Translating therapies for Huntington\u2019s disease from genetic animal models to clinical trials","volume":"1","author":"Hersch","year":"2004","journal-title":"NeuroRx"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/bph.13748","article-title":"Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases","volume":"175","author":"Berger","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/imm.12099","article-title":"Beyond DNA repair, the immunological role of PARP-1 and its siblings","volume":"139","author":"Rosado","year":"2013","journal-title":"Immunology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nrd1718","article-title":"Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors","volume":"4","author":"Jagtap","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_40","first-page":"201","article-title":"Inhibition of poly(ADP-ribosyl)ation in cancer: Old and new paradigms revisited","volume":"1846","author":"Lupo","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/iub.2048","article-title":"PARP inhibition by olaparib alleviates chronic asthma-associated remodeling features via modulating inflammasome signaling in mice","volume":"71","author":"Sethi","year":"2019","journal-title":"IUBMB Life"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"636","DOI":"10.2174\/1871527314666150430162841","article-title":"Poly(ADP-ribose) polymerase 1 (PARP-1) activation and Ca2+ permeable \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) channels in post-ischemic brain damage: New therapeutic opportunities?","volume":"14","author":"Gerace","year":"2015","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/hmg\/9.4.503","article-title":"Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice","volume":"9","author":"Wheeler","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease","volume":"205","author":"Bjorkqvist","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/13550280290100969","article-title":"Local neuroinflammation and the progression of Alzheimer\u2019s disease","volume":"8","author":"McGeer","year":"2002","journal-title":"J. Neurovirol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"9275","DOI":"10.1523\/JNEUROSCI.2614-05.2005","article-title":"Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration","volume":"25","author":"Cunningham","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e10248","DOI":"10.15252\/emmm.201810248","article-title":"Inflammasomes in neuroinflammatory and neurodegenerative diseases","volume":"11","author":"Voet","year":"2019","journal-title":"EMBO Mol. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.pneurobio.2012.08.004","article-title":"Therapeutic approaches to preventing cell death in Huntington disease","volume":"99","author":"Kaplan","year":"2012","journal-title":"Prog. Neurobiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12035-010-8124-6","article-title":"Poly (ADP-ribose) metabolism in brain and its role in ischemia pathology","volume":"41","author":"Strosznajder","year":"2010","journal-title":"Mol. Neurobiol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Xu, J.C., Fan, J., Wang, X., Eacker, S.M., Kam, T.I., Chen, L., Yin, X., Zhu, J., Chi, Z., and Jiang, H. (2016). Cultured networks of excitatory projection neurons and inhibitory interneurons for studying human cortical neurotoxicity. Sci. Transl. Med.","DOI":"10.1126\/scitranslmed.aad0623"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1007\/s11064-016-1864-6","article-title":"Neuroprotective effects of poly(ADP-ribose)polymerase inhibitor olaparib in transient cerebral ischemia","volume":"41","author":"Teng","year":"2016","journal-title":"Neurochem. Res."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/10\/2286\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:20:42Z","timestamp":1760178042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/10\/2286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,13]]},"references-count":51,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["cells9102286"],"URL":"https:\/\/doi.org\/10.3390\/cells9102286","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,13]]}}}